
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES126
The same study257 did not find a significant benefit associated with irbesartan as compared
with amlodipine in reducing the secondary composite endpoint of death from CV causes, nonfatal
MI, heart failure resulting in hospitalisation, a permanent neurologic deficit caused by a
cerebrovascular event, or lower limb amputation above the ankle. Level 1++

[@Andersen_2003]

